References
- Young MN, Inglessis I. Transcatheter aortic valve replacement: outcomes, indications, complications, and innovations. Curr Treat Options Cardiovasc Med. 2017;19:81. doi:10.1007/s11936-017-0580-0
- Franzone A, Pilgrim T, Stortecky S, Windecker S. Evolving indications for transcatheter aortic valve interventions. Curr Cardiol Rep. 2017;19:107. doi:10.1007/s11886-017-0921-3
- Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients. https://clinicaltrials.gov/ct2/show/NCT02701283. Accessed May 11, 2017.
- The PARTNER 3 Trial. The safety and effectiveness of the SAPIEN 3 transcatheter heart valve in low risk patients with aortic stenosis (P3). https://clinicaltrials.gov/ct2/show/NCT02675114. Accessed May 11, 2017.
- Hafiz A, Kalra A, Ramadan R, et al. Clinical or symptomatic leaflet thrombosis following transcatheter aortic valve replacement: insights from the U.S. FDA MAUDE database. Structural Heart. 2017;1:256–264. doi:10.1080/24748706.2017.1366086
- Rao G, Lopez-Jimenez F, Boyd J, et al. American Heart Association council on lifestyle and cardiometabolic health; Council on cardiovascular and stroke nursing; Council on cardiovascular surgery and anesthesia; Council on clinical cardiology; Council on functional genomics and translational biology; and stroke council. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: a scientific statement from the American Heart Association. Circulation. 2017;136:e172–e194.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006e1012. doi:10.1016/j.jclinepi.2009.06.005
- Higgins JPT, Green S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. 2011. http://handbook.cochrane.org.
- Pache G, Schoechlin S, Blanke P, et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263–2271.
- Leetmaa T, Hansson NC, Leipsic J, et al. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv. 2015;8:4. doi:10.1161/CIRCINTERVENTIONS.114.001596
- Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–2069. doi:10.1016/j.jacc.2016.08.010
- Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. JACC Cardiovasc Imaging. 2016. doi:10.1016/j.jcmg.2016.11.005
- Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–2024. doi:10.1056/NEJMoa1509233
- Vollema EM, Kong WKF, Katsanos S, et al. Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke. Eur Heart J. 2017;38:1207–1217. doi:10.1093/eurheartj/ehx031
- Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–2392. doi:10.1016/S0140-6736(17)30757-2
- Sondergaard L, De Backer O, Kofoed KF, et al. Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves. Eur Heart J. 2017;38:2201–2207. doi:10.1093/eurheartj/ehx369.
- Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015 April;8(4):pii: e001779. doi:10.1161/CIRCINTERVENTIONS.114.001779
- Cameron J, McCormick L, Meredith I, Gooley R Subclinical leaflet thickening in a novel mechanical expanded TAVI device. Presented at: PCR London Valves; September 20, 2016; London, UK.
- Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 2017;10:686–697. doi:10.1016/j.jcin.2017.01.045
- Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic valve thrombosis. J Am Coll Cardiol. 2017;69:2193–2211. doi:10.1016/j.jacc.2017.02.051
- Jilaihawi H, Asch FM, Manasse E, et al. Systematic CT methodology for the evaluation of subclinical leaflet thrombosis. JACC Cardiovasc Imaging. 2017;10:461–470. doi:10.1016/j.jcmg.2017.02.005
- Del Trigo M, Munoz-Garcia AJ, Wijeysundera HC, et al. Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol. 2016;67:644–655. doi:10.1016/j.jacc.2015.10.097
- Mangione FM, Jatene T, Gonçalves A, et al. Leaflet thrombosis in surgically explanted or post-mortem TAVR valves. JACC Cardiovasc Imaging. 2017;10:82–85. doi:10.1016/j.jcmg.2016.11.009.
- Akins CW, Miller DC, Turina MI, et al. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 2008;135:732–738. doi:10.1016/j.jtcvs.2007.12.002